Sublingual vs Oral (Swallowed) Ketamine: Absorption and Efficacy Differences

Sublingual vs oral (swallowed) ketamine differs mainly in how much ketamine reaches the bloodstream before the liver metabolizes it. Sublingual dosing can absorb partly through tissue under the tongue, while swallowed ketamine is absorbed through the gastrointestinal tract and undergoes more first-pass liver metabolism. That usually means sublingual treatment has a faster onset and somewhat higher bioavailability, but route choice should be made with a prescribing clinician because the evidence does not establish one route as universally more effective for depression.

Ketamine treatment plans also need to account for side effects, other medicines, medical history, and whether the patient can reliably use the selected formulation. See this guide to ketamine drug interactions and the overview of common ketamine side effects for related considerations.

How absorption differs

First-pass metabolism is the breakdown of a medicine by the liver after it is absorbed from the gut and before much of it reaches systemic circulation. When ketamine is swallowed, it travels through the gastrointestinal tract and portal circulation to the liver, where metabolism produces norketamine and other metabolites.

Sublingual ketamine, often supplied as a troche, rapidly dissolving tablet, or liquid, is held under the tongue. Some dissolved medication can pass through the highly vascular tissue there into systemic circulation. Some is still swallowed with saliva, so sublingual administration is a mixed route rather than a purely transmucosal one.

According to Rolan and colleagues, the absolute bioavailability of their studied racemic sublingual ketamine formulation was about 29%, although results can vary by formulation and technique. The authors reported this finding in the British Journal of Clinical Pharmacology. A clinical pharmacokinetic review by Peltoniemi and colleagues describes oral ketamine as having lower and variable bioavailability because of first-pass metabolism.

That difference has a practical consequence: holding a prescribed product under the tongue as directed matters. Swallowing it immediately changes the intended absorption pattern. Patients should not change the holding time, swallowing instructions, or dose on their own.

Onset, peak effects, and duration

Sublingual ketamine commonly has a faster onset because part of the dose can enter circulation through oral tissue. Swallowed ketamine generally takes longer because gastric emptying, intestinal absorption, food intake, and first-pass metabolism can affect the timing. Published estimates vary by product, dose, study design, and the endpoint measured, so timing should be treated as an expectation to discuss with the prescriber, not a fixed promise.

The different profiles may affect how a supervised treatment session is planned. A clinician may consider monitoring needs, transportation arrangements, recovery time, and the patient’s prior response. For a broader discussion of treatment timing, read how long ketamine effects last.

Does one route work better for depression?

There is not enough direct head-to-head research to conclude that sublingual ketamine is clinically superior to swallowed ketamine for depression. Higher bioavailability does not automatically mean a better outcome, because treatment response can also be affected by the formulation, dose plan, underlying condition, concurrent care, metabolism, and whether the medicine is used as instructed.

Small studies have reported antidepressant effects with sublingual ketamine in selected populations. For example, Lara and colleagues reported findings from a study of very-low-dose sublingual ketamine in refractory unipolar and bipolar depression, available through PubMed. Those results should not be read as proof that any particular sublingual dose or route will work for an individual patient.

Ketamine’s metabolites remain an active research topic. Zanos and colleagues examined antidepressant-related actions of ketamine metabolites in preclinical work, reported in Nature. Preclinical findings help inform research but do not replace route-specific clinical outcome data.

How clinicians and patients can compare the options

The best route is the one a patient can use safely and consistently within a clinician-designed plan. Taste tolerance, ability to follow the administration instructions, expected onset, previous response, nausea history, and other medications are all relevant. A patient who cannot keep a preparation under the tongue for the prescribed interval may not receive the expected sublingual exposure.

Do not assume that a higher milligram amount in one formulation is interchangeable with a higher amount in another. Prescribed ketamine doses depend on route, preparation, treatment goal, monitoring plan, and individual clinical factors. The ketamine troche dosage patient guide explains why formulation-specific instructions matter, while ketamine and alcohol safety risks covers an important avoidable interaction.